IFRA launches Benzyl Salicylate consortium

IFRA is launching a consortium to prepare an SCCS dossier for Benzyl Salicylate and invites potential participants to express their interest by close of business on Friday 19 June.

This dossier has been requested by the European Commission in the context of suspected endocrine disruptors (EDs) in cosmetic products. The deadline to submit the dossier is 15 January 2021. 

Three IFRA members have already expressed their interest, enabling us to legally start with the formation of a Consortium.

To express your interest, please send an email to Nicole Vaini, copying Cristina Arregui (carregui@ifraorg.org).


Dossier and consortium background

A preparatory data gap analysis has been performed by the IFRA Benzyl Salicylate ad-hoc Working Group (interested companies from the IFRA CMR Working Group). This group has agreed that additional tests may be needed. 

Estimated costs for the three additional tests are €80,000 to €85,000 (or more if some further data are needed in support of local lung toxicity assessment).

The cost for a consultant to prepare an SCCS dossier would be around €34,000 (£30,000). The cost of consortium project management would be additional. Costs will be split between the members of the Consortium. 

The Consortium will be fully self-financed. IFRA will not make any financial contribution and will only facilitate the exercise.

Getting involved

Please contact Nicole Vaini for further information, including a copy of the IFRA Consortium Protocol.  

To express your interest in joining the consortium, please contact Nicole Vaini (nvaini@ifraorg.org), copying Cristina Arregui (carregui@ifraorg.org).

The deadline for expressions of interest is close of business on Friday 19 June 2020.